logo-loader
viewImugene Ltd

Imugene doses first patient in phase-two study of cancer vaccine

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong speaks to Proactive Investors about the pharma and biotech company’s HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.
 
The company recently dosed its first patient in the phase II study of the HER-Vaxx cancer vaccine.
 
The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein.

Quick facts: Imugene Ltd

Price: 0.055 AUD

ASX:IMU
Market: ASX
Market Cap: $239.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

3 weeks, 3 days ago

2 min read